Li Rile, Wheeler Thomas, Dai Hong, Frolov Anna, Thompson Timothy, Ayala Gustavo
Department of Pathology, Baylor College of Medicine, Houston, TX 77030, USA.
Am J Surg Pathol. 2004 Jul;28(7):928-34. doi: 10.1097/00000478-200407000-00013.
Prostate cancer (PCa) is androgen dependent and is regulated by androgen/androgen receptor (AR) signaling pathway. However, the clinical significance of AR is in question. In this regard, we have correlated levels of AR expression with some well-established clinical and pathologic parameters and assessed the prognostic value of AR expression in PCa patients treated with radical prostatectomy.
A total of 640 cases treated with radical prostatectomy were used to build tissue microarrays. Normal prostate tissue, benign prostatic hyperplasia, and index tumor were cored in triplicate (0.6 mm). An array (2 mm) of 177 metastatic PCa was built as well. Slides were immunostained with an antibody to AR and Ki-67 and digitized. Correlations between AR expression and clinicopathologic variables were analyzed by the Spearman test. Biochemical recurrence-free survival analysis was performed using Kaplan-Meier analysis, and Cox proportional hazard regression was used to determine the probability of disease recurrence.
AR was found in epithelial nuclei of both benign and cancer tissues. AR index was higher in normal prostate tissues than that in PCa and benign prostatic hyperplasia and decreased in metastases than PCa. High level of AR expression was correlated with clinical stage, lymph node status, extracapsular extension, seminal vesicle invasion, and Gleason score. High levels of AR status also correlated with high Ki-67 index (r = 0.211, P = 0.0000). By Kaplan-Meier actuarial model, high expression of AR was predictive of a higher probability of recurrence (P = 0.0046, hazards ratio 2.72 [confidence interval 1.28-4.011]). By multivariate analysis, a high level of AR expression was an independent prognostic indicator of biochemical recurrence-free survival (P = 0.0042; hazards ratio 2.422 [confidence interval 1.32-4.44]).
High levels of AR are associated with increased proliferation, markers of aggressive disease and are predictive of decreased biochemical recurrence-free survival independently. This confirms the role of AR in tumor growth and progression in hormonally naive PCa.
前列腺癌(PCa)依赖雄激素,并受雄激素/雄激素受体(AR)信号通路调控。然而,AR的临床意义尚存在疑问。在这方面,我们将AR表达水平与一些公认的临床和病理参数进行了关联分析,并评估了AR表达在接受根治性前列腺切除术的PCa患者中的预后价值。
共选取640例行根治性前列腺切除术的病例构建组织芯片。正常前列腺组织、良性前列腺增生及肿瘤标本均钻取3次(0.6毫米)。还构建了包含177例转移性PCa的芯片(2毫米)。玻片用抗AR和Ki-67抗体进行免疫染色并数字化。采用Spearman检验分析AR表达与临床病理变量之间的相关性。使用Kaplan-Meier分析进行生化无复发生存分析,并采用Cox比例风险回归确定疾病复发的概率。
在良性和癌组织的上皮细胞核中均发现了AR。正常前列腺组织中的AR指数高于PCa和良性前列腺增生,且转移灶中的AR指数低于PCa。AR高表达与临床分期、淋巴结状态、包膜外侵犯、精囊侵犯及Gleason评分相关。AR高水平状态也与高Ki-67指数相关(r = 0.211,P = 0.0000)。通过Kaplan-Meier精算模型,AR高表达预示着更高的复发概率(P = 0.0046,风险比2.72 [置信区间1.28 - 4.011])。多因素分析显示,AR高表达是生化无复发生存的独立预后指标(P = 0.0042;风险比2.422 [置信区间1.32 - 4.44])。
AR高水平与增殖增加、侵袭性疾病标志物相关,且独立预示生化无复发生存期缩短。这证实了AR在激素初治PCa肿瘤生长和进展中的作用。